Literature DB >> 26772199

Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.

Shawn H MacVane1,2.   

Abstract

Bacterial infections are a frequent cause of hospitalization, and nosocomial infections are an increasingly common condition, particularly within the acute/critical care setting. Infection control practices and new antimicrobial development have primarily focused on gram-positive bacteria; however, in recent years, the incidence of infections caused by gram-negative bacteria has risen considerably in intensive care units. Infections caused by multidrug-resistant (MDR) gram-negative organisms are associated with high morbidity and mortality, with significant direct and indirect costs resulting from prolonged hospitalizations due to antibiotic treatment failures. Of particular concern is the increasing prevalence of antimicrobial resistance to β-lactam antibiotics (including carbapenems) among Pseudomonas aeruginosa and Acinetobacter baumannii and, recently, among pathogens of the Enterobacteriaceae family. Treatment options for infections caused by these pathogens are limited. Antimicrobial stewardship programs focus on optimizing the appropriate use of currently available antimicrobial agents with the goals of improving outcomes for patients with infections caused by MDR gram-negative organisms, slowing the progression of antimicrobial resistance, and reducing hospital costs. Newly approved treatment options are available, such as β-lactam/β-lactamase inhibitor combinations, which significantly extend the armamentarium against MDR gram-negative bacteria.
© The Author(s) 2016.

Entities:  

Keywords:  cost-effectiveness; critical care; gram-negative infections; intensive care; multidrug-resistant bacteria; outcomes; β-lactamase inhibitor

Mesh:

Substances:

Year:  2016        PMID: 26772199     DOI: 10.1177/0885066615619895

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  40 in total

1.  Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network.

Authors:  Jordi Rello; Cristina Sarda; Djamel Mokart; Kostoula Arvaniti; Murat Akova; Alexis Tabah; Elie Azoulay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-09       Impact factor: 3.267

2.  Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.

Authors:  Scott R Evans; Thuy Tien T Tran; Andrea M Hujer; Carol B Hill; Kristine M Hujer; Jose R Mediavilla; Claudia Manca; T Nicholas Domitrovic; Federico Perez; Michael Farmer; Kelsey M Pitzer; Brigid M Wilson; Barry N Kreiswirth; Robin Patel; Michael R Jacobs; Liang Chen; Vance G Fowler; Henry F Chambers; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

3.  Effects of Antibiotic Treatment with Piperacillin/Tazobactam versus Ceftriaxone on the Composition of the Murine Gut Microbiota.

Authors:  Carola Venturini; Bethany Bowring; Alicia Fajardo-Lubian; Carol Devine; Jonathan Iredell
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development.

Authors:  Sherwin K B Sy; Luning Zhuang; Serubbabel Sy; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2019-05       Impact factor: 6.447

5.  The Mla pathway is critical for Pseudomonas aeruginosa resistance to outer membrane permeabilization and host innate immune clearance.

Authors:  Jason Munguia; Doris L LaRock; Hannah Tsunemoto; Joshua Olson; Ingrid Cornax; Joseph Pogliano; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2017-08-26       Impact factor: 4.599

6.  Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.

Authors:  Helio S Sader; Mariana Castanheira; Dee Shortridge; Rodrigo E Mendes; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

7.  Surveillance of Antibiotic Use and Resistance in Intensive Care Units (SARI).

Authors:  Cornelius Remschmidt; Sandra Schneider; Elisabeth Meyer; Barbara Schroeren-Boersch; Petra Gastmeier; Frank Schwab
Journal:  Dtsch Arztebl Int       Date:  2017-12-15       Impact factor: 5.594

8.  Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.

Authors:  Rajbharan Yadav; Phillip J Bergen; Kate E Rogers; Carl M J Kirkpatrick; Steven C Wallis; Yuling Huang; Jürgen B Bulitta; David L Paterson; Jeffrey Lipman; Roger L Nation; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

9.  Tracking Multidrug-Resistant Klebsiella pneumoniae from an Italian Hospital: Molecular Epidemiology and Surveillance by PFGE, RAPD and PCR-Based Resistance Genes Prevalence.

Authors:  Giancarlo Ripabelli; Manuela Tamburro; Giuliana Guerrizio; Incoronata Fanelli; Romeo Flocco; Massimiliano Scutellà; Michela L Sammarco
Journal:  Curr Microbiol       Date:  2018-03-09       Impact factor: 2.188

10.  Risk Factors for Gastrointestinal Colonization and Acquisition of Carbapenem-Resistant Gram-Negative Bacteria among Patients in Intensive Care Units in Thailand.

Authors:  Anong Kiddee; Kanit Assawatheptawee; Anamai Na-Udom; Pornpit Treebupachatsakul; Apirath Wangteeraprasert; Timothy R Walsh; Pannika R Niumsup
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.